{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:16:01Z","timestamp":1785366961765,"version":"3.55.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T00:00:00Z","timestamp":1625184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Pseudocirrhosis is characterized by radiological changes in the liver that resemble cirrhosis, but with more rapid onset and progression. Though reported most frequently in patients with metastatic breast cancer, little is known about its prognostic factors and impact on breast cancer outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this observational study, we reviewed abdominal CT and\/or MRI scan reports of all patients with invasive breast cancer diagnosed at our center, during a ten-year period, to identify patients with pseudocirrhosis. Exclusion criteria included lack of baseline imaging, pre-existing cirrhosis, hepatitis B or C, other chronic liver diseases, or heavy alcohol use. Routine descriptive statistical measures were used. Survival distributions were estimated using Kaplan-Meier method, and Cox regression was used for multivariate analysis. Two-tailed <jats:italic>p<\/jats:italic> &amp;lt; 0.05 was considered significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty-six patients were included \u2013 all were females, median age was 57.5 years, and 90% were Caucasian; 86% of primary tumors were hormone-receptor positive and 17% were HER2 positive. Most patients (98%) had metastatic disease with liver involvement (94%), and were heavily pre-treated \u2013 97% with chemotherapy, 85% with hormonal therapy, and 19% with anti-HER2 agents. Median interval from breast cancer diagnosis to pseudocirrhosis was 75.4 months (IQR 35.2-115.3 months). Thirty-six percentage of patients had \u22651 signs of portal hypertension and 49% had \u22651 signs of hepatocellular failure. Pseudocirrhosis led to permanent discontinuation of chemotherapy, endocrine therapy, and all systemic therapies in 29%, 31%, and 20% patients, respectively. Median overall survival from diagnosis of pseudocirrhosis was 10.0 months (95%CI 5.2-14.8 months). On multivariate analysis, coagulopathy, hyperbilirubinemia, hypoalbuminemia, and cancer progression were independently predictive of mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this largest series, to date, of breast cancer with pseudocirrhosis, the latter was often complicated by portal hypertension and hepatocellular failure, and markedly impacted breast cancer management. Survival was shorter for patients who developed hepatocellular failure.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.679163","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T07:20:30Z","timestamp":1625210430000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Pseudocirrhosis in Breast Cancer \u2013 Experience From an Academic Cancer Center"],"prefix":"10.3389","volume":"11","author":[{"given":"Dharmesh","family":"Gopalakrishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ain","family":"Shajihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei S.","family":"Purysko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jame","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00781680","article-title":"Hepar Lobatum Carcinomatosum Due to Metastatic Breast Carcinoma","volume":"410","author":"Honma","year":"1987","journal-title":"Virchows Arch A Pathol Anat Histopathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-018-1592-2","article-title":"Pseudocirrhosis","volume":"43","author":"Leshchinskiy","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.clinimag.2006.09.028","article-title":"Frequency of Hepatic Contour Abnormalities and Signs of Portal Hypertension at CT in Patients Receiving Chemotherapy for Breast Cancer Metastatic to the Liver","volume":"31","author":"Qayyum","year":"2007","journal-title":"Clin Imaging"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2013.19.2.190","article-title":"Pseudocirrhosis as a Complication After Chemotherapy for Hepatic Metastasis From Breast Cancer","volume":"19","author":"Jeong","year":"2013","journal-title":"Clin Mol Hepatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.163.6.7992734","article-title":"CT of the Liver in Patients With Metastatic Breast Carcinoma Treated by Chemotherapy: Findings Simulating Cirrhosis","volume":"163","author":"Young","year":"1994","journal-title":"AJR Am J Roentgenol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3747\/co.19.840","article-title":"Medullary Thyroid Cancer and Pseudocirrhosis: Case Report and Literature Review","volume":"19","author":"Harry","year":"2012","journal-title":"Curr Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/SMJ.0b013e3181d82d50","article-title":"Pseudocirrhosis in Metastatic Esophageal Cancer","volume":"103","author":"Kobashigawa","year":"2010","journal-title":"South Med J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2016.1096","article-title":"Pseudocirrhosis Caused by Regorafenib in an Advanced Rectal Cancer Patient With Multiple Liver Metastases","volume":"6","author":"Kumamoto","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.14309\/crj.2018.29","article-title":"Pseudocirrhosis in a Patient With New-Onset Dysphagia and History of Ovarian Carcinoma","volume":"5","author":"Zanazanian","year":"2018","journal-title":"ACG Case Rep J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s13244-015-0436-7","article-title":"Cancer Therapy Related Complications in the Liver, Pancreas, and Biliary System: An Imaging Perspective","volume":"6","author":"Ngo","year":"2015","journal-title":"Insights Imaging"},{"key":"B11","unstructured":"American Cancer Society Breast Cancer Facts & Figures\u00a02019-20202019"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1075-122x.2005.21699.x","article-title":"Breast Cancer-Related Pseudocirrhosis and Esophageal Varices","volume":"11","author":"Chandrakar","year":"2005","journal-title":"Breast J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.182.3.1820651","article-title":"Hepatic Capsular Retraction in Metastatic Carcinoma of the Breast Occurring With Increase or Decrease in Size of Subjacent Metastasis","volume":"182","author":"Fennessy","year":"2004","journal-title":"AJR Am J Roentgenol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-018-0865-5","article-title":"Pseudocirrhosis After Chemotherapy in Breast Cancer, Case Reports","volume":"25","author":"Aoyagi","year":"2018","journal-title":"Breast Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2016.12.005","article-title":"Pseudocirrhosis in Metastatic Breast Cancer","volume":"41","author":"Hidalgo-Blanco","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"B16","first-page":"328","article-title":"Pseudocirrhosis in Metastatic Breast Cancer","volume":"19","author":"Zeina","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"B17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4143\/crt.2014.46.1.98","article-title":"Pseudocirrhosis of Breast Cancer Metastases to the Liver Treated by Chemotherapy","volume":"46","author":"Lee","year":"2014","journal-title":"Cancer Res Treat"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1159\/000448066","article-title":"Pseudocirrhosis: A Case Series and Literature Review","volume":"10","author":"Adike","year":"2016","journal-title":"Case Rep Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231044","article-title":"Recurrent Metastatic Breast Cancer Presenting With Portal Hypertension and Pseudocirrhosis","volume":"12","author":"Adler","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9332-9","article-title":"Diffuse Desmoplastic Metastatic Breast Cancer Simulating Cirrhosis With Severe Portal Hypertension: A Case of \u201cPseudocirrhosis\u201d","volume":"52","author":"Sass","year":"2007","journal-title":"Dig Dis Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)74872-8","article-title":"Cirrhosis With Steatohepatitis After Adjuvant Tamoxifen","volume":"353","author":"Oien","year":"1999","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S0140-6736(05)78493-2","article-title":"Tamoxifen-Induced Fatty Liver in Patients With Breast Cancer","volume":"351","author":"Ogawa","year":"1998","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28720","article-title":"Pseudocirrhosis and Liver Failure in Patients With Metastatic Breast Cancer After Treatment With Palbociclib","volume":"65","author":"Vuppalanchi","year":"2017","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000327010","article-title":"Liver Failure on the Background of Pseudocirrhosis in Patients With Liver Metastasis From Breast Cancer, Who Responded to Treatment","volume":"34","author":"Sonnenblick","year":"2011","journal-title":"Onkologie"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05311-y","article-title":"Clinical Features of Pseudocirrhosis in Metastatic Breast Cancer","volume":"177","author":"Oliai","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000695","article-title":"Metastatic Breast Cancer and Pseudocirrhosis: An Unknown Clinical Entity","volume":"5","author":"Engelman","year":"2020","journal-title":"ESMO Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2016.09.008","article-title":"Use of Routinely Available Clinical, Nutritional, and Functional Criteria to Classify Cachexia in Advanced Cancer Patients","volume":"36","author":"Vigano","year":"2017","journal-title":"Clin Nutr"},{"key":"B28","volume-title":"SEER Cancer Statistics Review, 1975-2017","author":"Howlader","year":"2020"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.679163\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T07:20:35Z","timestamp":1625210435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.679163\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,2]]},"references-count":28,"alternative-id":["10.3389\/fonc.2021.679163"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.679163","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,2]]},"article-number":"679163"}}